Amalya Sargsyan: One of Oncodaily’s top 10 promising drugs is showing great resuts at ESMOGI24
Amalya Sargsyan shared a post by
“Exciting Updates!
𝐁𝐨𝐭𝐞𝐧𝐬𝐢𝐥𝐢𝐦𝐚𝐛 one of OncoDaily‘s ‘𝟏𝟎 𝐌𝐨𝐬𝐭 𝐏𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐫𝐮𝐠𝐬 𝐍𝐨𝐭 𝐘𝐞𝐭 𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐝’ for 2024, is showing great results against MSS colorectal cancer. Our editorial team predicted its potential, and it’s incredible to witness this progress..
Wishing the entire team continued success and hope to see Botensilimab move from the ‘not approved’ list to the ‘approved’ one soon!
The rapid advancements in oncology are truly inspiring. Identifying and highlighting 𝐩𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠 𝐧𝐞𝐰 𝐝𝐫𝐮𝐠𝐬 is more important than ever.
Interested in more? See our full top 10 list and watch this space for updates on other candidates.”
Quoting
“NEST Trial responses to date.
What’s particularly of note is the deepening of the responses with longer time to brew . The pattern and lack of recurrence speaks to curative potential of immunotherapy for both MSS and MSI-High tumors.”
Source: Amalya Sargsyan/LinkedIn and /LinkedIn
Dr. Amalya Sargsyan is a Medical Oncologist at Yeolyan Center, a Research Physician at the Immune Oncology Research Institute, and Senior Editor at Oncodaily. She holds an MD from Yerevan State Medical University and an MSc in Precision Medicine from the University of Cyprus.
Dr. Sargsyan completed her clinical training at the Bank of Cyprus Oncology Center and has been honored with an ASCO IDEA award. Her research focuses on the potential of novel immune checkpoint inhibitors (ICI) in low- and middle-income countries (LMICs), aiming to bridge disparities and enhance access to innovative cancer care.
Dr. Pashtoon Kasi is a medical oncologist and researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Within his roles at Weill Cornell Medicine, he holds the positions of Director for Colorectal Cancer Research and Precision Medicine Director for Liquid Biopsy Research at the Englander Institute of Precision Medicine. Previously, Dr. Kasi served as an Associate Professor of Medicine in the Division of Hematology and Oncology at the University of lowa, following positions as an Assistant Professor of Medicine and Oncology at both the University of lowa and Mayo Clinic.
His research primarily focuses on “liquid biopsies,” particularly circulating tumor DNA (cDNA) and circulating tumor cells (CTCs). Dr. Kasi is also recognized as an author and editor of several significant books, including “Research: What, Why, and How: A Treatise from Researchers to Researchers” and “Impact of Circulating Tumor DNA (ctDNA) in Patients with Gastrointestinal Malignancies.” His scholarly contributions extend to over 100 publications in esteemed peer-reviewed journals.